Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension-Reference-Cited by-同舟云学术

Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension

Published:2022-07 Issue:3 Volume:12 Page:
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Nikkho Sylvia M.¹^ORCID,Richter Manuel J.²^ORCID,Shen Eric³^ORCID,Abman Steven H.⁴,Antoniou Katerina⁵,Chung Jonathan⁶,Fernandes Peter⁷,Hassoun Paul⁸,Lazarus Howard M.⁹^ORCID,Olschewski Horst¹⁰,Piccari Lucilla¹¹,Psotka Mitchell¹²¹³,Saggar Rajan¹⁴,Shlobin Oksana A.¹⁵,Stockbridge Norman¹⁶,Vitulo Patrizio¹⁷,Vizza Carmine Dario¹⁸,Wort Stephen J.¹⁹²⁰,Nathan Steven D.¹⁵^ORCID

Affiliation:

1. Global Clinical Development Bayer AG Berlin Germany

2. Department of Internal Medicine Pulmonary Hypertension Division Universities of Giessen and Marburg Lung Center (UGMLC) Giessen Germany

3. Global Medical Affairs United Therapeutics Corporation Silver Spring Maryland USA

4. School of Medicine and Children's Hospital University of Colorado—Anschutz Medical Campus Aurora Colorado USA

5. Department of Thoracic Medicine University of Crete School of Medicine Heraklion Crete Greece

6. Department of Radiology The University of Chicago Medicine Chicago Illinois USA

7. Regulatory, Safety and Quality Department Bellerophon Therapeutics Inc Warren New Jersey USA

8. Department of Medicine, Division of Pulmonary and Critical Care Medicine Johns Hopkins University Baltimore Maryland USA

9. Altavant Sciences Cary North Carolina USA

10. Division of Pulmonology, Department of Internal Medicine Medical University of Graz Graz Steiermark Austria

11. Department of Pulmonary Medicine Hospital del Mar, Pulmonary Hypertension Unit Barcelona Catalunya Spain

12. Inova Heart and Vascular Institute Falls Church Virginia USA

13. Division of Cardiology and Nephrology Food and Drug Administration Silver Spring Maryland USA

14. Lung & Heart‐Lung Transplant and Pulmonary Hypertension Programs University of California Los Angeles David Geffen School of Medicine Los Angeles California USA

15. Advanced Lung Disease and Transplant Program Inova Heart and Vascular Institute Falls Church Virginia USA

16. Division of Cardiology and Nephrology US Food and Drug Administration Silver Spring Maryland USA

17. Therapies, Department of Pulmonary Medicine IRCCS Mediterranean Institute for Transplantation and Advanced Specialized Palermo Sicilia Italy

18. Pulmonary Hypertension Unit University of Rome La Sapienza Rome Lazio Italy

19. National Pulmonary Hypertension Service at Royal Brompton Hospital London UK

20. National Heart and Lung Institute, Imperial College London UK

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pul2.12127

Reference95 articles.

1. A global view of pulmonary hypertension

2. Haemodynamic definitions and updated clinical classification of pulmonary hypertension

3. Pulmonary hypertension in chronic lung disease and hypoxia

4. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases

5. Group III Pulmonary Hypertension

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future;Frontiers in Medicine;2024-01-17

2. Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension;Pulmonary Circulation;2024-01

3. Unmasking a Silent Threat: Improving Pulmonary Hypertension Screening Methods for Interstitial Lung Disease Patients;Medicina;2023-12-28

4. Die Lunge: Ausgangspunkt vieler Erkrankungen;Pneumo News;2023-12

5. Diagnose Algorithmus der pulmonalen Hypertonie und Screening-Verfahren;Pneumologie;2023-11